Clinical trials: Neoplasm, Squamous Cell
Basal Cell Carcinoma, Squamous Cell Carcinoma
Electronic Brachytherapy for the Treatment of NMSC
The objective of this study is to record recurrence in patients treated for nonmelanoma (basal cell and squamous cell carcinomas) skin cancer using the Xoft Axxent Electronic Brachytherapy System.
- Trial name
- NCT01016899
- Testing
- electronic brachytherapy
- Where
- 5 sites in United States
- Volunteers
- 187 people
- Sponsor
- Xoft, Inc.
Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma
This is a single-center, non-interventional, observational study that evaluates the correlation of circulating tumor DNA (ctDNA) testing to cancer relapse for participants with squamous cell carcinomas (HNC) of the head and neck…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Squamous Cell Carcinoma of Skin, Cutaneous Squamous Cell Carcinoma (CSCC)
- Trial name
- NCT06606028
- Testing
- Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of California, San Francisco
Head and Neck Cancer
Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma
The purpose of this study is to explore the efficiency and safety of anti-Programmed death-1 (PD-1) immunotherapy, tislelizumab, combined with EGFR-tyrosine kinase inhibitor (TKI), afatinib as a new neoadjuvant treatment regimen…
- Trial name
- neoCHANCE-1 (NCT05517330)
- Testing
- Tislelizumab, Afatinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- West China Hospital
Oral Squamous Cell Carcinomas
Heterogeneity of Oral Squamous Cell Carcinoma Analysis by Single Cell RNA Sequencing
The goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and leucoplasic) counterparts by scRNAseq in OSCC…
- Trial name
- HOASIS (NCT06861036)
- Testing
- Biospecimen, Blood sampling
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Leon Berard
Esophageal Cancer by AJCC V8 Stage
Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
To evaluate the efficacy and safety of patients with advanced esophageal squamous cell carcinoma treated with camrelizumab combined with Apatinib mesylate plus short-course chemotherapy versus standard chemotherapy in first line
- Trial name
- NCT05738434
- Testing
- Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib, Camrelizumab+Chemotherapy→Camrelizumab
- Where
- China
- Volunteers
- 188 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Head and Neck Cancer
Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004163
- Testing
- Trastuzumab
- Where
- 10 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Carcinoma
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
Esophageal squamous cell carcinoma is a common malignancy in China. Although neoadjuvant chemoradiotherapy followed by esophagectomy remains a standard modality for locally advanced esophageal squamous cell carcinoma…
- Trial name
- NCT05937438
- Testing
- Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Anhui Provincial Hospital
Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
This phase II trial studies how well chemotherapy before surgery and radiation therapy works compared to surgery and radiation therapy alone in treating patients with nasal and paranasal sinus cancer that can be removed by…
- Trial name
- NCT03493425
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- 154 sites in United States
- Volunteers
- 82 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Head and Neck Squamous Cell Carcinoma
Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)
This proposed study will evaluate the efficacy and safety of preoperative administration of Toripalimab or Toripalimab combined with nab-paclitaxel and carboplatin in Head and Neck Squamous Cell Carcinoma (HNSCC) who are about to…
- Trial name
- NCT04807140
- Testing
- Toripalimab, nab-paclitaxel, carboplatin, Toripalimab, Surgical resection
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Advanced Esophageal Squamous Cell Cancer
Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
This study aimed to evaluate the safety and feasibility of neoadjuvant tislelizumab combined with chemoradiotherapy in patients with resectable esophageal squamous cell cancer.
- Trial name
- NCT05323890
- Testing
- Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shandong Cancer Hospital and Institute
Esophageal Squamous Cell Carcinoma
Dynamic ctDNA Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
This study is a prospective, multicenter, open-label, observational cohort study. The primary endpoint is pathological complete response (pCR), and the secondary endpoints include R0 resection rate, ctDNA clearance rate, major…
- Trial name
- ctDNA (NCT06103890)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Medical University Fourth Hospital
Carcinoma, Squamous Cell
Acitretin Plasma Levels Under Hemodialysis
Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.
- Trial name
- NCT00488384
- Testing
- Chemopreventive application (Acitretin)
- Where
- Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- Günther Hofbauer
HRAS Gene Mutation, HNSCC
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy
An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN).
- Trial name
- AIM-HN/SEQ-HN (NCT03719690)
- Testing
- Tipifarnib, HRAS Detection Assay
- Where
- 102 sites in United States, Australia and 14 more
- Volunteers
- 296 people
- Sponsor
- Kura Oncology, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Squamous Cell Carcinoma of the Head and Neck
Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
Objective: To determine the Overall Response Rate (ORR) to Imprime PGG + pembrolizumab in subjects with advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Safety: To characterize the safety of Imprime PGG +…
- Trial name
- NCT03246685
- Testing
- Imprime PGG, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- HiberCell, Inc.
Squamous Cell Carcinoma of Head and Neck
NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN
Subjects will receive treatment with nivolumab monotherapy at 240mg flat dose as a 30 minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death…
- Trial name
- NIVACTOR (NCT05802290)
- Testing
- Nivolumab 240 MG in 24 ML Injection
- Where
- 23 sites in Italy
- Volunteers
- 124 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Head and Neck Cancer, Squamous Cell Carcinoma
Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
In this single-arm study, pathologically confirmed advanced head and neck squamous cell carcinoma will be enrolled to investigate the efficacy and safety of Camrelizumab in combination With albumin paclitaxel and cisplatin.
- Trial name
- NCT04922450
- Testing
- PD-1 inhibitor, Albumin Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Hunan Cancer Hospital
Esophageal Squamous Cell Neoplasia (ESCN)
RFA for Flat Type High-grade and Medium-grade Intraepithelial Squamous Neoplasia
Multicenter, prospective cohort clinical trial in greater China
- Trial name
- REACH (NCT02953418)
- Testing
- Radiofrequency ablation
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Medtronic - MITG
Squamous Cell Carcinoma, Neoplasia
Optical Imaging of Head and Neck Cancer
This study examines if certain imaging techniques and devices can aid the surgeon in detecting cancer during the surgical procedure.
- Conditions
- Squamous Cell Carcinoma, Neoplasia, Head and Neck Cancer
- Trial name
- NCT01456143
- Testing
- High Resolution Microendoscopy (HRME), Proflavine hemisulfate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sharmila Anandasabapathy, MD
Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells.
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00002515
- Testing
- filgrastim, carboplatin, thiotepa
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center